HNGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Hinge Health Inc (HNGE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive analyst sentiment, and significant market potential in the digital musculoskeletal therapy space. Despite minor price target reductions, analysts maintain positive ratings, and the company's financial performance and growth trajectory are compelling. The technical indicators also suggest a bullish trend, making it a suitable long-term investment.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 72.868, suggesting the stock is approaching overbought territory but not yet signaling a reversal. Moving averages are converging, and the price is trading above key pivot levels, with resistance at R2: 44.307. Overall, the technical indicators suggest a bullish trend.
Strong Q4 revenue growth of 45.60% YoY, exceeding estimates.
Projected 2026 revenue growth to $732-$742 million.
Expansion of corporate client base by 25% in Q
Introduction of an AI care assistant to enhance service efficiency.
Gross margin improvement to 84.36%, showcasing operational efficiency.
Minor price target reductions from analysts, reflecting cautious optimism.
Lack of consistent profitability despite strong revenue growth.
In Q4 2025, Hinge Health reported a 45.60% YoY revenue increase to $170.7 million, net income growth of 14.64% YoY to $31.1 million, and EPS growth of 5.71% YoY to 0.37. Gross margin improved to 84.36%, up 2.94% YoY. The company also achieved a 65% increase in free cash flow to $61.5 million.
Analysts maintain a positive outlook on Hinge Health with multiple Buy and Overweight ratings. While price targets have been slightly reduced (e.g., from $65 to $50 by Evercore ISI), analysts highlight strong financial performance, significant growth potential in the $60B musculoskeletal industry, and industry-leading margins. The consensus suggests the stock is undervalued with room for long-term growth.
